Business Wire

NTT

Share
NTT: Conclusion of a Cooperation Agreement with ITER

NTT Corporation (NTT, President & CEO: Jun Sawada) concluded a Cooperation Agreement on the ITER Project with the ITER International Fusion Energy Organization (ITER Organization).
By supporting the ITER Project, which has the objective of building the world’s first experimental hydrogen fusion reactor, NTT will accelerate “Development of innovative environment and energy technologies”, and contribute to the reduction of the environmental impact of customers, companies and society.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200514005951/en/

1. Background
The ITER Project is an extraordinarily large international project that has the objective of building the world’s first experimental hydrogen fusion reactor (ITER) to prove the scientific and technical feasibility of the fusion energy for peaceful purposes. The ITER Organization, an international organization with seven members – Japan, the European Union, Russia, the United States, South Korea, China, and India – is engaged in the ITER Project.

NTT is aiming at “Zero Environmental Impact” by supporting customers, enterprises, and society in reducing their impact on the environment through our R&D aimed at creating innovations that break through conventional limitations and by pursuing business activities designed to decrease deleterious effects on the environment. For example, NTT is preparing to establish the Space Environment and Energy Laboratories, which will undertake research with the goal of creating innovative energy and environmental technologies.
NTT assumes the use of photonic technologies developed for IOWN* concept, and will work to extend the current ICT technologies, which would benefit the ITER Project.
*IOWN (Innovative Optical and Wireless Network) is a future communications infrastructure to create a smarter world by using cutting-edge technologies like photonics and computing technologies.
https://www.rd.ntt/e/iown/

2. Scope of Cooperation
Under the strategic intent of this Cooperation Agreement, NTT will collaborate in the following areas.

  • Exploration of innovative future Information and Communication Technology, including ultra-high-speed network, ultra-low latency network connectivity, data storage, computing, and global network infrastructure.
  • Exploration of the concept “IOWN” including All-Photonics Network, Digital Twin Computing, and Cognitive Foundation.

This is the first time that the ITER Organization has signed a Long Term Non-Commercial Cooperation Agreement with a private Japanese company. As a general ICT player capable of providing full-stack, full-lifecycle services on a global scale, the NTT Group will collaborate on information distribution and control platforms in preparation for ITER’s first plasma in 2025 and beyond.
NTT will work out the details and conclude an implementation agreement.

3. Executive statements
“With an aim of achieving zero environmental impact, NTT is conducting R&D to create the innovations needed to achieve this goal, and carrying out its business activities in a manner that reduces its effects on the environment. Safe and permanent fusion energy is one of the most promising technologies in this important endeavor. We believe that NTT’s groundbreaking R&D activities, including IOWN, and our ability to construct global infrastructure can make a valuable contribution to the ITER Organization, a leading research entity in this area. Under this agreement, we will work closely with the ITER Organization to demonstrate the feasibility of fusion power at an industrial scale for the first time in human history.”
-Jun Sawada , President & CEO, NTT

“We, with the seven ITER Members, believe that fusion power can become a clean and safe vital contributor to the global energy mix for our civilization starting in this century for numerous millennium, and the progress of the ITER Project is essential for that path. I am pleased to have global ICT companies like NTT as one of our long-term non-commercial collaboration partners, with the solid capacity to develop advanced global ICT technologies as well as the capability to envision innovative future technologies strategies such as the IOWN concept that fusion will definitively need.”
-Bernard Bigot , Director-General, the ITER Organization

About NTT
NTT believes in resolving social issues through our business operations by applying technology for good. We help clients accelerate growth and innovate for current and new business models. Our services include digital business consulting, technology and managed services for cybersecurity, applications, workplace, cloud, data center and networks all supported by our deep industry expertise and innovation.
As a top 5 global technology and business solutions provider, our diverse teams operate in 88 countries and regions and deliver services to over 190 of them. We serve 85% of Fortune Global 100 companies and thousands of other clients and communities around the world.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma18.12.2025 12:00:00 CET | Press release

BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancerFDA Fast Track Designation reflects the potential of BGB-B2033 in an area of high unmet need BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment. “The FDA awards Fast Track Designation to therapies that show potential to address an unmet medical need in serious or life-threatening conditions. The FDA’s decision reflects the encouraging profile of BGB-B2033 in advanced hepatocellular carcinoma, where patients continue to face limited treatment options,” said Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer at BeOne. BeOne is currentl

NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 10:53:00 CET | Press release

NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a

Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release

The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki

Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release

Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release

Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye